San Francisco, United States
Phyla is a biotechnology and healthcare startup founded in 2014 with headquarters in the United States. The company's slogan "Making benzoyl peroxide obsolete for acne" encapsulates its mission to revolutionize acne treatment. By leveraging cutting-edge microbiome research and bacteriophage technology, Phyla stands out in the industry.
The company's innovative approach focuses on addressing the root cause of acne and other chronic diseases, specifically targeting bacterial overgrowth without causing collateral damage. Phyla's products have been clinically proven to selectively eliminate harmful bacteria, thereby improving acne and recalibrating the microbiome for long-term skin health.
Moreover, Phyla's bacteriophage platform demonstrates the potential to address various bacterial diseases, reflecting the scalability and applicability of its technology beyond acne treatment.
Notably, Phyla received a significant Series A investment on 07 December 2023, with Shiseido emerging as the lead investor, showcasing the confidence and support from a key player in the healthcare and beauty industry.
In summary, Phyla's pioneering approach, backed by robust investment and strategic partnerships, positions the company as a promising player in the biotechnology and healthcare sectors, with the potential to make a significant impact on the treatment of acne and other related conditions.
